Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 4/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377655 | 0.90 | GABRA2 (0.47) | AGPAT2ANO1LMNAMAPK1CYP1A2 | |
| SCHEMBL21044449 | 0.87 | AGPAT2 (0.52) | AGPAT2PTGDR2DHFR | |
| SCHEMBL17595047 | 0.79 | GABRA2 (0.59) | LMNACYP1A2GABRA2GABRB2TARBP2 | |
| SCHEMBL4364443 | 0.78 | GAA (0.50) | LMNAMAPK1GAAMAPT | |
| SCHEMBL3327719 | 0.75 | CYP1A2 (0.61) | MAPK1CYP1A2GABRA2GABRB2MAPT | |
| SCHEMBL19194799 | 0.75 | GABRA2 (0.54) | LMNACYP1A2GABRA2GABRB2TARBP2 | |
| SCHEMBL11626779 | 0.74 | KDM4E (0.53) | LMNAGABRA2GABRB2GAAMAPT | |
| Trifluoroacetic Acid SCHEMBL5389154 | 0.73 | AGPAT2 (0.60) | AGPAT2PTGDR2DHFR | |
| SCHEMBL1546491 | 0.72 | MAPK1 (0.50) | MAPK1GAAMAPT | |
| SCHEMBL30850464 | 0.72 | EIF4EBP1 (0.48) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191451-B1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INST SCIENCE & TECH SCHOOL CORP (JP) | 2019-06-05 | — | — | EP | claimed |
| US-20170217889-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2017-08-03 | — | — | US | claimed |
| EP-3191451-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | Okinawa Institute of Science and Technology School Corporation (JP) | 2017-07-19 | — | — | EP | claimed |
| WO-2016038890-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2016-03-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217889-A1 | 4-SUBSTITUTED PYRIDINE-2,6-DICARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING SAME | PDK2, PKD1, PDHA2 | AGPAT2 771/4885ANO1 1415/4885LMNA 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.